What Happens After Stopping a GLP-1 Medication?

The short answer: regain is common, not uniform

Clinical trials and pooled evidence show that weight frequently rises after a GLP-1 or related weight-management medication is discontinued. That does not mean every person regains all the weight, or that everyone follows the same timeline. Starting weight, amount lost, treatment duration, reason for stopping, other care, health conditions, and follow-up time can all shape what is observed.

A 2026 BMJ systematic review examined 37 studies involving 9,341 adults and modeled the average pace of regain after weight-management medication ended. The authors cautioned that many studies had short follow-up or risk of bias. A pooled average or model projection describes a group. It cannot forecast what a particular person will weigh months later.

What the STEP 1 extension found after semaglutide

In the STEP 1 extension, a selected group of trial completers who had received semaglutide 2.4 mg plus a lifestyle intervention lost an average 17.3% of body weight during the main treatment period. Over the following 52 weeks off treatment, they regained an average 11.6 percentage points. The group still had an average net loss from its original baseline rather than returning completely to the starting point.

The extension also reported that several cardiometabolic improvements moved back toward baseline after treatment withdrawal. Its limits matter: the follow-up involved 327 people from selected sites who had completed the main trial, and treatment and the formal lifestyle intervention stopped together. The result is strong evidence of average regain in that study setting, not proof that every former semaglutide user will regain two-thirds of prior loss.

What SURMOUNT-4 found after tirzepatide withdrawal

SURMOUNT-4 used a randomized withdrawal design. After an initial tirzepatide treatment period, participants who met the trial criteria were assigned either to continue tirzepatide or switch to placebo. Over the next 52 weeks, the placebo-switch group had an average 14.0% weight increase, while the continued-treatment group lost an additional 5.5% on average.

The two groups followed different weight trajectories under the trial protocol. The result still does not establish an individual stopping plan. Participants were selected trial completers, the withdrawal was part of a controlled protocol, and care outside a trial can look different. The figures should not be used to calculate how much a specific person will regain or when it will happen.

Why the 2026 real-world cohort looked different

A Cleveland Clinic retrospective cohort followed 7,938 adults in Ohio and Florida after discontinuation of semaglutide or tirzepatide. Among those treated for obesity, the average change from discontinuation to one year later was a 0.5% increase, with substantial person-to-person variation. Many people restarted the original medicine, switched to another obesity treatment, or received other weight-management care during follow-up.

This study does not overturn the withdrawal trials. It describes what happened in routine care, where treatment after the recorded stop was not held constant. Because it was observational, it cannot prove that any restart, switch, or lifestyle service caused a particular outcome. Trials estimate an effect under a defined protocol. Real-world records show a more mixed pathway with additional decisions along the way.

What evidence cannot yet tell you about tapering or switching

There is no single proven tapering, dose-spacing, cycling, switching, or restarting protocol that current evidence establishes for everyone after GLP-1 treatment. Social-media schedules and clinic anecdotes are not substitutes for comparative trials. A product label may contain directions for discontinuation in specific situations, but that is different from evidence that a general taper prevents weight regain.

Do not change a prescription based on this article. The evidence summarized here does not provide instructions for stopping, tapering, spacing doses, switching, cycling, or restarting. Discuss any treatment change with a licensed clinician who knows your history.

What Happens After Stopping a GLP-1 Medication? questions